Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCATCo Regulatory News (CAT)

  • This share is currently suspended. It was suspended at a price of 37.50
  • There is currently no data for CAT

Portfolio Update

19 Feb 2019 12:00

RNS Number : 5011Q
CATCo Reinsurance Opps Fund Ltd
19 February 2019
 

 

 

 

CATCo Reinsurance Opportunities Fund Ltd. ("the Company")

Portfolio Update

 

To: SFM, London Stock Exchange and Bermuda Stock Exchange

Date: 19 February, 2019

 

2019 Portfolio Highlights

· 2019 portfolio indicative maximum net return, on a no loss basis, is approximately 30 percent (net of hedging costs, fees and expenses) on invested capital (2018: 23 percent).

· This includes the remaining 2018 mid-year deals (c. 25 percent of portfolio) and renewed 1 January 2019 deals.

· Max capital exposure to a worst-case single event 10 percent

 

2018 Portfolio Summary

· 2018 unaudited net asset value ("NAV") return for the C Shares was -35.7 percent.

· Breakdown of unaudited loss reserves by event in an amount as a percent of 1 January 2018 NAV (of the Cs) as follows:

o Hurricanes Florence and Michael: c. 15.3 percent

o Typhoon Jebi: c. 8.5 percent

o California Wildfires: c. 35.3 percent

o Attritional c. 1.5 percent

Due to the nature of inherent uncertainty with underlying catastrophic losses the above reserves may be subject to future favourable or adverse development

 

Ordinary Shares:

· The total Side Pocket Investments ("SPIs") held by calendar year of underwriting are as follows as a percentage of the Company's 31 December 2018 NAV:

o 2015: c. 2 percent (c. 1.2 percent at 31 December 2017)

o 2016: c. 11 percent (c. 6.1 percent at 31 December 2017)

o 2017: c. 42 percent. (c. 41.5 percent at 31 December 2017). Actual claims paid represent c. 75 percent of total 2017 losses recorded

o 2018: c. 21 percent. Actual claims paid represent c. 35 percent of total 2018 losses recorded

· The 2018 annual dividend was announced on 31 January 2019. Annual dividend of $0.0265 in respect of each of the Ordinary Shares for the year to 31 December 2018 are expected to be paid to Shareholders on 25 February 2019.

· After reflecting 2017 and 2018 SPIs and loss reserves, the Ordinary Shares, net of dividend declared in 2019, will have c. 16 percent of NAV participating in the 2019 portfolio.

· As at 31 December 2018, the cash held by the Ordinary Shares represented c.1 percent of NAV.

 

C Shares

· The total Side Pocket Investments ("SPIs") held as a percentage of the Company's 31 December 2018 NAV:

o 2018: c. 47 percent. Actual claims paid to date represent c. 35 percent of total 2018 losses recorded

· The 2018 annual dividend was announced on 31 January 2019. Annual dividends of $0.0445 in respect of each of the C Shares for the year to 31 December 2018 are expected to be paid to Shareholders on 25 February 2019.

· After reflecting 2018 SPIs and loss reserves, the C shares, post dividend, will have c. 45 percent participating in the 2019 portfolio.

· As at 31 December 2018, the cash held by the C Shares represented c.1% of NAV

 

Any capital (net of Side Pockets) released from the 2018 mid-year deals may be returned to investors at the discretion of the Board subject to consultation with Shareholders.

 

This announcement contains Inside Information as defined under the Market Abuse Regulation (EU) No. 596/2014.

 

 

 

For further information:

Judith Wynne

General Counsel

Markel CATCo Investment Management Ltd.

Telephone: +1 441 493 9005

Email: judith.wynne@markelcatco.com

 

Mark Way

Chief Operating Officer

Markel CATCo Investment Management Ltd.

Telephone: +1 441 493 9001

Email: mark.way@markelcatco.com

 

David Benda / Hugh Jonathan

Numis Securities Limited

Telephone: +44 (0) 20 7260 1000

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
PFUBBGDDCUBBGCC
Date   Source Headline
29th Mar 201111:40 amRNSIssue of Equity
29th Mar 201111:36 amRNSDirector/PDMR Shareholding
7th Mar 20111:49 pmRNSNet Asset Value(s)
7th Feb 20118:30 amRNSPortfolio Update
7th Feb 20118:11 amRNSNet Asset Value(s)
14th Jan 20117:00 amRNSPortfolio Update
7th Jan 20113:33 pmRNSHolding(s) in Company
23rd Dec 201011:00 amRNSHolding(s) in Company
20th Dec 20107:00 amRNSResult of Placing and Admission to SFM
13th Jul 20064:12 pmRNSHolding(s) in Company
10th Jul 20063:20 pmRNSHolding(s) in Company
7th Jul 20062:51 pmRNSOffer for Cambridge Antibody
3rd Jul 20064:56 pmRNSDirectorate Change
30th Jun 20064:12 pmRNSHolding(s) in Company
30th Jun 20064:06 pmRNSDelisting
30th Jun 200610:27 amRNSAdditional Listing
30th Jun 20067:02 amRNSOffer for Cambridge Antibody
27th Jun 20062:26 pmRNSHolding(s) in Company
27th Jun 200612:34 pmRNSHolding(s) in Company
23rd Jun 20062:25 pmRNSAppointment of Directors
22nd Jun 20063:07 pmRNSRule 8.3- CAT
22nd Jun 200611:31 amRNSCAT Limited appoints new CE
22nd Jun 200611:11 amRNSEPT Disclosure
22nd Jun 200611:09 amRNSEPT Disclosure
22nd Jun 20067:02 amRNSOffer for Cambridge Antibody
21st Jun 20065:11 pmRNSRule 8.1- C.A.T.
21st Jun 200611:30 amRNSEPT Disclosure
21st Jun 200610:20 amRNSEPT Disclosure
20th Jun 200610:36 amRNSEPT Disclosure
20th Jun 200610:36 amRNSEPT Disclosure
19th Jun 20063:25 pmRNSRule 8.3 - Cambridge Antibody
19th Jun 20061:07 pmRNSRule 8.3- (CAT)
19th Jun 200611:30 amRNSEPT Disclosure
19th Jun 200611:23 amRNSEPT Disclosure
19th Jun 200610:33 amRNSEPT Disclosure
16th Jun 200611:45 amRNSEPT Disclosure
16th Jun 200611:24 amRNSEPT Disclosure
16th Jun 200611:08 amRNSEPT Disclosure
15th Jun 20065:01 pmRNSEPT Disclosure
15th Jun 20062:48 pmRNSRule 8.3- (CAT)
15th Jun 20062:17 pmRNSRule 2.10 Announcement
15th Jun 200612:45 pmRNSEPT Disclosure
15th Jun 200611:36 amRNSEPT Disclosure
14th Jun 20063:38 pmRNSRule 8.3- Cambridge Antibody
14th Jun 20063:05 pmRNSRule 8.3- Cambridge Antibody
14th Jun 20061:43 pmRNSRule 8.3- (CAT)
14th Jun 200611:36 amRNSEPT Disclosure
14th Jun 200611:15 amRNSEPT Disclosure
14th Jun 200610:59 amRNSEPT Disclosure
14th Jun 200610:23 amRNSEPT Disclosure

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.